Single-group interventional study (n=20) testing intravenous low-dose ketamine (0.5 mg/kg) for treatment-resistant depression, with MRS and inflammatory serum markers as secondary measures.
Open single-group treatment study administering a single IV infusion of ketamine 0.5 mg/kg to participants with treatment-resistant depression (n=20).
Outcomes include clinical response in depression and mechanistic measures: glutamate neurotransmission by magnetic resonance spectroscopy and inflammatory serum markers (IL-6, TNF-alpha).
IV ketamine 0.5 mg/kg for treatment-resistant depression patients (single-group).
Single intravenous infusion 0.5 mg/kg.